Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
<p>Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.</p>
Salvato in:
| Autore principale: | |
|---|---|
| Altri autori: | , , , , , , , , , , , , , , , , , , , , , , |
| Pubblicazione: |
2025
|
| Soggetti: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1849927632014016512 |
|---|---|
| author | Amr El Zawily (14851115) |
| author2 | Frederick S. Vizeacoumar (14851118) Renuka Dahiya (14851121) Sara L. Banerjee (14851124) Kalpana K. Bhanumathy (14851127) Hussain Elhasasna (14851130) Glinton Hanover (14851133) Jessica C. Sharpe (14851136) Malkon G. Sanchez (14851139) Paul Greidanus (14851142) R. Greg Stacey (14851145) Kyung-Mee Moon (14851148) Ilya Alexandrov (14851151) Juha P. Himanen (14851154) Dimitar B. Nikolov (14851157) Humphrey Fonge (14851160) Aaron P. White (14851163) Leonard J. Foster (8976302) Bingcheng Wang (14851166) Behzad M. Toosi (14851169) Nicolas Bisson (14851172) Tajib A. Mirzabekov (14851175) Franco J. Vizeacoumar (14851178) Andrew Freywald (14851181) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Amr El Zawily (14851115) Frederick S. Vizeacoumar (14851118) Renuka Dahiya (14851121) Sara L. Banerjee (14851124) Kalpana K. Bhanumathy (14851127) Hussain Elhasasna (14851130) Glinton Hanover (14851133) Jessica C. Sharpe (14851136) Malkon G. Sanchez (14851139) Paul Greidanus (14851142) R. Greg Stacey (14851145) Kyung-Mee Moon (14851148) Ilya Alexandrov (14851151) Juha P. Himanen (14851154) Dimitar B. Nikolov (14851157) Humphrey Fonge (14851160) Aaron P. White (14851163) Leonard J. Foster (8976302) Bingcheng Wang (14851166) Behzad M. Toosi (14851169) Nicolas Bisson (14851172) Tajib A. Mirzabekov (14851175) Franco J. Vizeacoumar (14851178) Andrew Freywald (14851181) |
| author_role | author |
| dc.creator.none.fl_str_mv | Amr El Zawily (14851115) Frederick S. Vizeacoumar (14851118) Renuka Dahiya (14851121) Sara L. Banerjee (14851124) Kalpana K. Bhanumathy (14851127) Hussain Elhasasna (14851130) Glinton Hanover (14851133) Jessica C. Sharpe (14851136) Malkon G. Sanchez (14851139) Paul Greidanus (14851142) R. Greg Stacey (14851145) Kyung-Mee Moon (14851148) Ilya Alexandrov (14851151) Juha P. Himanen (14851154) Dimitar B. Nikolov (14851157) Humphrey Fonge (14851160) Aaron P. White (14851163) Leonard J. Foster (8976302) Bingcheng Wang (14851166) Behzad M. Toosi (14851169) Nicolas Bisson (14851172) Tajib A. Mirzabekov (14851175) Franco J. Vizeacoumar (14851178) Andrew Freywald (14851181) |
| dc.date.none.fl_str_mv | 2025-11-25T13:29:02Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30709335 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Table_S3_from_A_Multipronged_Unbiased_Strategy_Guides_the_Development_of_an_Anti-EGFR_EPHA2_Bispecific_Antibody_for_Combination_Cancer_Therapy/30709335 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Database resources Drug Targets Cell surface receptor drug targets Proteomics Systems Biology Translational Research |
| dc.title.none.fl_str_mv | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_446f6a85224675669058d570789cde85 |
| identifier_str_mv | 10.1158/1078-0432.30709335 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30709335 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer TherapyAmr El Zawily (14851115)Frederick S. Vizeacoumar (14851118)Renuka Dahiya (14851121)Sara L. Banerjee (14851124)Kalpana K. Bhanumathy (14851127)Hussain Elhasasna (14851130)Glinton Hanover (14851133)Jessica C. Sharpe (14851136)Malkon G. Sanchez (14851139)Paul Greidanus (14851142)R. Greg Stacey (14851145)Kyung-Mee Moon (14851148)Ilya Alexandrov (14851151)Juha P. Himanen (14851154)Dimitar B. Nikolov (14851157)Humphrey Fonge (14851160)Aaron P. White (14851163)Leonard J. Foster (8976302)Bingcheng Wang (14851166)Behzad M. Toosi (14851169)Nicolas Bisson (14851172)Tajib A. Mirzabekov (14851175)Franco J. Vizeacoumar (14851178)Andrew Freywald (14851181)CancerMolecular and Cellular BiologyTherapeutic Research and DevelopmentMethods and TechnologyComputational MethodsDatabase resourcesDrug TargetsCell surface receptor drug targetsProteomicsSystems BiologyTranslational Research<p>Table S3: GO analysis of phosphorylated proteins differentially expressed in αEPHA2-Cond and cIgG-Tr cells.</p>2025-11-25T13:29:02ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30709335https://figshare.com/articles/dataset/Supplementary_Table_S3_from_A_Multipronged_Unbiased_Strategy_Guides_the_Development_of_an_Anti-EGFR_EPHA2_Bispecific_Antibody_for_Combination_Cancer_Therapy/30709335CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307093352025-11-25T13:29:02Z |
| spellingShingle | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy Amr El Zawily (14851115) Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Database resources Drug Targets Cell surface receptor drug targets Proteomics Systems Biology Translational Research |
| status_str | publishedVersion |
| title | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| title_full | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| title_fullStr | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| title_full_unstemmed | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| title_short | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| title_sort | Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy |
| topic | Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Computational Methods Database resources Drug Targets Cell surface receptor drug targets Proteomics Systems Biology Translational Research |